Pharmaceutical prior art challenge - montelukast sodium
REQUEST # 30680-S1-01 Pharmaceutical Prior Art Challenge – Montelukast Sodium Requesting Organization: SUBMIT PRIOR ART BY: February 20, 2009 MANAGER: Kevin C. Stark, Ph.D. SOLUTION PROVIDER HELP DESK EMAIL Opportunity $50,000 Reward for legitimizing the validity of patents based on technical literature research. If one or more references show a
patent to be invalid, then the respondent who found the research
REQUEST DESCRIPTION
patent is invalid. Sending in research and all
activities on the website also earn Points towards
seeks public literature about montelukast sodium,
profit sharing by users of about 5% of Article
the active ingredient in Singulair™. Public
literature for this project can be dated no later
A brief introduction on this project is below, and
more information on this patent study is online at:
Article One Partners uses the power of the global
online community to discover public literature
(called Prior Art) that can legitimize or invalidate
selected patents. The patents, the Latest Date for
the public literature and details about the patents
BACKGROUND SUMMARY
are described in Patent Studies. The Patent
The active ingredient in Singulair, montelukast
Study for this challenge is MRK 473. Learn more
sodium, is a selective and orally active
leukotriene receptor antagonist that inhibits the
Montelukast sodium is described by the structural
RESPONDING TO THIS REQUEST
formula in Figure 1 above, CAS number [151767-
If you can apply your knowledge, search skills or
02-1] and one of its full IUPAC chemical names
network of referrals to identify relevant prior art,
is Sodium 1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-
quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-
Responses are submitted using the Response
methylethyl)phenyl]propyl]thio]methyl]cyclopropaneac
form provided in the Study. Their website has
more information on this particular challenge and
defines what prior art is, and where to find it.
The Singulair patent has “composition” claims
Respondents are required to register online with
and “method” claims. A composition claim is one
that covers a chemical structure or formulation
regardless of what it may be used for. A method
A $50,000 reward will be distributed to the
claim covers particular use(s) of the composition.
respondent who is the first submitter of prior art
The Singulair patent also has claims to the
used by Article One to form an opinion that the
combination of the claimed composition and
23611 Chagrin Blvd., Suite 320, Cleveland, OH 44122 • 216-295-4800 • www.ninesigma.com
RFP format and graphics Copyright 2007 NineSigma, Inc
NineSigma Request # 30680-S1-01 Pharmaceutical Prior Art Challenge – Montelukast Sodium
another compound, for example, a non-steroidal anti-inflammatory drug (NSAID). Relevant prior art includes:
1. disclosure of the composition shown in
2. disclosure of the compositions shown in
the patent (note there is a correction to the formula of the composition of claim 7; see the pdf copy of the patent online);
3. use of the composition to treat asthma; 4. use of the composition to treat
synthesis, the action, or the release of SRS-A or leukotrienes.
23611 Chagrin Blvd., Suite 320, Cleveland, OH 44122 • 216-295-4800 • www.ninesigma.com
Yasuyuki Ishikawa E-mail: yishikawa@uprrp.edu Date of Birth: Oct. 10, 1947(naturalized U.S. citizen): Marital Status: Married, one child Education Tokyo Institute of Technology, Japan, B.S. in Chemistry 1971 University of Iowa, Iowa City, Iowa, Ph.D. in Chemistry 1976 Employment Professor of Chemistry University of Puerto Rico, Rio Piedras IMS Visiting Professor University of Puerto Rico, Ri
Kopfschmerzen in der Schwangerschaft Kopfschmerzen während der Schwangerschaft sind nicht ungewöhnlich, vor allem in den ersten 3 Monaten. Falls Sie bereits vor der Schwangerschaft mit Kopfschmerzen zu kämpfen hatten, ist es in der Schwangerschaft oft noch schlimmer. Eine häufige Ursache dafür wird in der plötzlichen Hormon-Flut und Kreislaufumstellung vermutet, was auch durc
REQUEST # 30680-S1-01